Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed.

1. A sulfotransferase from a gut microbe acts on diverse phenolic sulfate compounds, including acetaminophen sulfate.PNAS nexus · 2026
   Article
2. Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson's disease.Gut microbes · 2025
   Review
3. Drug-microbiota interactions: an emerging priority for precision medicine.Signal transduction and targeted therapy · 2023
   Review
4. Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges.International journal of molecular sciences · 2023
   Review
5. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.Nature reviews. Rheumatology · 2020
   Review
6. Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.Metabolites · 2020
   Review
7. Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream.Proceedings of the National Academy of Sciences of the United States of America · 2020
   Article
8. Metabolites · 2019
   Article
9. Quantitative systems pharmacology and the personalized drug-microbiota-diet axis.Current opinion in systems biology · 2017
   Review
10. Microbiome-wide association studies link dynamic microbial consortia to disease.Nature · 2016
    Review
11. Pharmacometabolomics in Early-Phase Clinical Development.Clinical and translational science · 2016
    Review
12. The intestinal microbiome and surgical disease.Current problems in surgery · 2016
    Review
13. Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease.EBioMedicine · 2016
    Review
14. From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine.Frontiers in pharmacology · 2016
    Review
15. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.Translational psychiatry · 2015
    Article
16. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity.Liver international : official journal of the International Association for the Study of the Liver · 2015
    Article
17. Towards structural systems pharmacology to study complex diseases and personalized medicine.PLoS computational biology · 2014
    Review
18. Genetic and chemical characterization of ibuprofen degradation by Sphingomonas Ibu-2.Microbiology (Reading, England) · 2013
    Article
19. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes.Gut pathogens · 2012
    Article
20. Do interactions between gut ecology and environmental chemicals contribute to obesity and diabetes?Environmental health perspectives · 2012
    Review

Corrections and comments

• Comment on
  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as